Merus
Merus is a clinical-stage oncology company that utilizes its proprietary Multiclonics platform to discover and develop therapeutic antibodies. The company focuses on creating new treatments for cancer patients through a pipeline of clinical trials. It has recently been acquired by and operates as part of Genmab.
Biotechnology
Oncology
Healthcare
Funding summary
- Total raised
- €125.5M
- Funding rounds
- 3
- Exit
- acquisition
- Exit value
- €6.8B
Investors in Merus
Investors on record for Merus. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Merus?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors